Vandetanib and indwelling pleural catheter for non-small cell lung cancer with recurrent malignant pleural effusion

BACKGROUND: Non-small-cell lung cancer patients with malignant pleural effusion have a poor overall median survival (4.3 months). Vascular endothelial growth factor (VEGF) is a key regulator of pleural effusion production. It is unknown if pharmacological inhibition of VEGF signaling modifies the di...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Massarelli, Erminia, Onn, Amir, Marom, Edith M., Alden, Christine M., Liu, Diane D., Tran, Hai T., Mino, Barbara, Wistuba, Ignacio I., Faiz, Saadia A., Bashoura, Lara, Eapen, George A., Morice, Rodolfo C., Jack Lee, J., Hong, Waun K., Herbst, Roy S., Jimenez, Carlos A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160385/
https://ncbi.nlm.nih.gov/pubmed/24913066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2014.04.002
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares